Diagnostics

A simulation study looked at whether adding MRI to standard digital breast tomosynthesis (DBT) improves breast cancer screening for women with dense breasts. The results show a trade-off: MRI can catch a few more cancers, but it also leads to many more false positives and unnecessary biopsies. For most average-risk women, adding MRI prevented only […]

A new study shows that ultrasensitive blood and urine testing can help identify patients with muscle-invasive bladder cancer (MIBC) who may safely avoid radical cystectomy. This “liquid biopsy” approach detects tiny traces of cancer that standard scans miss, enabling personalized, bladder-preserving care instead of a one-size-fits-all surgery approach. The study used two types of DNA

Colorectal cancer (CRC) is a major cause of death worldwide, and early-onset cases in people under 50 have risen sharply in Western countries. Although early detection can often cure the disease, common blood markers like CEA are not specific enough for reliable screening. In a recent study, researchers tested a new approach called Thermal Liquid

Researchers are shifting toward blood-based biomarker tests to detect colorectal adenomas (CRAs), which are precancerous lesions that can lead to colorectal cancer. While colonoscopy and stool tests (FIT) are standard, blood tests are more convenient and may better detect non-bleeding lesions, improving patient compliance. Key approaches include noncoding RNAs (such as microRNAs and circular RNAs),

Ovarian cancer is one of the deadliest gynecological cancers, partly because early detection is difficult. Traditional blood markers like CA125 and HE4 often miss early-stage disease, and tissue biopsies cannot capture the full complexity of tumors. cfDNA methylation liquid biopsy is emerging as a non-invasive and highly sensitive alternative for diagnosis, prognosis, and monitoring treatment.

Colorectal cancer (CRC) can be cured if found early, but current screening tools like endoscopy and the CEA blood test often miss early-stage disease. Researchers have developed a new blood test called the SERS eCRC Metabolites Model (SCMM), which combines nanotechnology and artificial intelligence to detect tiny metabolic changes linked to early cancer. The team

New research shows that adding a deep-learning AI tool to chest CT interpretation can significantly improve radiologists’ ability to detect early-stage lung cancer while maintaining accuracy. The study found that AI assistance increased detection sensitivity by 24.3% without significantly increasing false positives. It also made readings faster, reducing the average scan interpretation time by about

Researchers have developed a new blood test that could greatly improve early detection of pancreatic cancer, a disease that is often diagnosed too late to treat effectively. Scientists combined four protein markers—CA19-9, THBS2, and two newly identified markers, ANPEP and PIGR—into a single test. Using all four markers together significantly increased accuracy. The test correctly

Lung cancer is still the leading cause of cancer-related death worldwide, largely due to smoking and environmental exposure. It mainly includes non-small cell lung cancer, which makes up most cases and has a low long-term survival rate, and small cell lung cancer, which is less common but more aggressive. Current diagnosis relies heavily on CT

The FDA has approved Darzalex Faspro (daratumumab with hyaluronidase) combined with bortezomib, lenalidomide, and dexamethasone (VRd) for adults newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The approval is based on a study of 395 patients showing that adding Darzalex Faspro to VRd improved outcomes: 52.3% of patients achieved MRD negativity versus